Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal(R), the Company’s lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal. The term of the patent will expire on March 19, 2023. If a Patent Term Extension under the Hatch-Waxman Act is granted, patent life in the US could extend into 2028.
“We are pleased to strengthen our intellectual property portfolio and expect additional patent grants surrounding Androxal,” stated Joseph Podolski, President and Chief Executive Officer of Repros Therapeutics. “This patent is important to the protection of our Androxal program. If Repros can successfully develop Androxal, it could become a leading treatment for low testosterone in men.”